Small molecules useful in the treatment of inflammatory disease
申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
公开号:US06353013B1
公开(公告)日:2002-03-05
Novel compounds of the formula I
which are useful for treating or preventing inflammatory and immune cell-mediated diseases. Exemplary compounds are:
5-(R)-(4-bromobenzyl)-3-(3-chloro-5-nitrophenyl)-5-methylimidazoline-2,4-dione; and,
5-(R)-(4-bromobenzyl)-3-(3-chloro-5-cyanophenyl)-5-methylimidazoline-2,4-dione.
[EN] 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE ET DE 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2013068935A1
公开(公告)日:2013-05-16
The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
申请人:ACTELION PHARMACEUTICALS LTD
公开号:US20150158855A1
公开(公告)日:2015-06-11
The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I)
wherein Ar
1
, Q, and R
1
to R
5
are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
申请人:Bolli Martin
公开号:US09150566B2
公开(公告)日:2015-10-06
The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I)
wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.